Oncolytics Biotech Set for Breakout on Promising Trial Data
AI Prediction of Oncolytics Biotech Inc. (ONCY)
Oncolytics Biotech is poised for potential growth due to its lead candidate, Pelareorep, targeting gastrointestinal cancers with upcoming significant catalysts including interim data from clinical trials.
Oncolytics Biotech focuses on developing Pelareorep, an immunotherapeutic agent targeting various cancers, with an emphasis on gastrointestinal cancers. The company is currently engaged in multiple Phase 2 clinical trials, particularly for colorectal and pancreatic cancers. Pelareorep has shown promising results in earlier trials, and interim data expected by the end of 2026 could be a significant catalyst. The company's strategic shift to the U.S. and its focus on securing additional financing through strategic partnerships augment its potential for operational success and growth. The upcoming clinical data, if positive, could substantially impact the company's valuation and stock price.
ONCY Report Information
Prediction Date2026-04-02
Close @ Prediction$0.93
Mkt Cap108m
IPO DateN/a
AI-derived Information
Recent News for ONCY
- Apr 6, 9:00 am — Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer (GlobeNewswire)
- Apr 1, 9:00 am — Oncolytics Biotech Completes Domicile Change to the United States (GlobeNewswire)
- Mar 19, 9:00 am — Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 (GlobeNewswire)
- Mar 5, 9:00 am — Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types (PR Newswire)
- Mar 3, 9:00 am — Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion (PR Newswire)
- Mar 2, 9:00 am — Oncolytics Biotech Launches Randomized Colorectal Cancer Study (GlobeNewswire)
- Feb 25, 9:00 am — Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 (PR Newswire)
- Feb 24, 10:58 am — Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge (PR Newswire)
- Feb 24, 9:00 am — Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer (GlobeNewswire)
- Feb 17, 11:17 am — New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
- Feb 5, 9:35 am — $207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire)
- Feb 5, 8:55 am — Oncolytics receives FDA Fast Track Designation for pelareorep (TipRanks)
NDAPR (News-Driven AI Prediction Revision) events for ONCY
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest